Skip to search formSkip to main contentSkip to account menu

interferon beta-1b 0.3 MG Injection [Extavia]

Known as: EXTAVIA KIT, INTERFERON BETA-1B 0.25 mg in 1.0 mL SUBCUTANEOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [Extavia], Extavia 0.3 MG Injection 
National Institutes of Health

Related topics

Related topics

10 relations
Albumin Human, USPDrug AllergyExtaviaInjection

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results
Antibodies against biopharmaceuticals (anti-drug antibodies, ADA) have been a well-integrated part of the clinical care of… 
2017
2017
Patient satisfaction with ExtaviPro™ 30G, a new auto-injector for administering interferon β-1b in multiple sclerosis: results from a real-world, observational EXCHANGE study
BackgroundPatients with multiple sclerosis (MS) receiving long-term, subcutaneous interferon β-1b (IFN β-1b; Extavia®) often… 
2016
2016
Medication Adherence, Persistence and Cost in Multiple Sclerosis Patients: Oral vs Parenteral Treatment
The primary purpose of this study was to evaluate the medication adherence of MS patients to oral and parenteral self… 
2015
2015
Interferones beta (Avonex®, Betaferon®, Extavia®, Rebif®: riesgo de microangiopatía trombótica y síndrome nefrótico
2013
2013
Ocular side effects of drugs used in the treatment of multiple sclerosis
2013
2013
ExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study
Background The ExtaviJect® 30G autoinjector was developed to facilitate parenteral self-administration of interferon beta-1b… 
Review
2013
Review
2013
Autoinjectors for administration of interferon beta-1b in multiple sclerosis: patient preferences and the ExtaviPro™ 30G and Betacomfort® devices
Background The ExtaviPro™ 30G autoinjector has been developed for self-administration of interferon beta-1b (Extavia®), which is… 
2012
2012
Farmacoutilizzazione e considerazioni economiche nella terapia della sclerosi multipla: il ruolo della Received Daily Dose
BackgroundMultiple sclerosis, a demyelinating disease of the central nervous system, is the most common cause of neurological… 
Review
2010
Review
2010
Autoinjector Improves Injection-related Tolerability Issues in Patients with Multiple Sclerosis - Exploring the New ExtaviJect™ 30G System for the Injection of Interferon Beta-1b
Most of the current disease-modifying therapies available for the treatment of multiple sclerosis (MS) are administered by… 
2009
2009
FDA actions in brief, October 2009 (Sabril, Helixate FS, Valcyte, Metozolv ODT, Xyzal, Zevalin, Extavia, Astepro, Zenpep, Bepreve)
Recent FDA approvals (through October 2009) related to Sabril, Helixate FS, Valcyte, Metozolv ODT, Xyzal, Zevalin, Extavia… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)